These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24392977)

  • 1. Reliably basing conclusions on subgroups of randomized clinical trials.
    Koch A; Framke T
    J Biopharm Stat; 2014; 24(1):42-57. PubMed ID: 24392977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and evaluation of multiregional trials with heterogeneous treatment effect across regions.
    Chen CT; Hung HM; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1037-50. PubMed ID: 22946948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An urn model for odds-ratio-based response-adaptive phase III clinical trials for two or more treatments.
    Basak GK; Biswas A; Volkov S
    J Biopharm Stat; 2009 Sep; 19(5):838-56. PubMed ID: 20183447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical principles: myths or facts?
    Sylvester R
    Onkologie; 2003 Dec; 26(6):520-1. PubMed ID: 14709923
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized clinical trial: myths around elementary statistical principles.
    Edler L; Kopp-Schneider A
    Onkologie; 2003 Dec; 26(6):551-6. PubMed ID: 14709929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of statistical and regulatory issues in the planning, analysis, and interpretation of subgroup analyses in confirmatory clinical trials.
    Hemmings R
    J Biopharm Stat; 2014; 24(1):4-18. PubMed ID: 24392975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confirmatory clinical trials with an adaptive design.
    Koch A
    Biom J; 2006 Aug; 48(4):574-85. PubMed ID: 16972708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?
    Hernández AV; Boersma E; Murray GD; Habbema JD; Steyerberg EW
    Am Heart J; 2006 Feb; 151(2):257-64. PubMed ID: 16442886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of statistical planning to address subgroups in confirmatory clinical trials.
    Koch GG; Schwartz TA
    J Biopharm Stat; 2014; 24(1):72-93. PubMed ID: 24392979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Introduction to the statistical aspects of planning clinical oncologic phase III studies].
    Sylvester R; Minder CE
    Urologe A; 1995 Sep; 34(5):367-73. PubMed ID: 7483152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A flexible design for multiple armed screening trials.
    Sargent DJ; Goldberg RM
    Stat Med; 2001 Apr; 20(7):1051-60. PubMed ID: 11276035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How practical are adaptive designs likely to be for confirmatory trials?
    Gould AL
    Biom J; 2006 Aug; 48(4):644-9; discussion 660-2. PubMed ID: 16972716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
    Serebruany VL
    Cardiology; 2011; 120(3):169-71. PubMed ID: 22418766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying sensitivity analyses to overall survival in cancer clinical trials.
    Wolff SN
    J Clin Oncol; 2010 Jul; 28(19):e323; author reply e324. PubMed ID: 20516448
    [No Abstract]   [Full Text] [Related]  

  • 17. Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors.
    Zhang S; Liang F; Li W; Hu X
    J Clin Oncol; 2015 May; 33(15):1697-702. PubMed ID: 25897150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress.
    Biswas A
    Stat Methods Med Res; 2001 Oct; 10(5):353-64. PubMed ID: 11697227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian models for subgroup analysis in clinical trials.
    Jones HE; Ohlssen DI; Neuenschwander B; Racine A; Branson M
    Clin Trials; 2011 Apr; 8(2):129-43. PubMed ID: 21282293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough.
    Thabut G; Crestani B; Porcher R; Richeldi L
    Eur Respir J; 2015 Sep; 46(3):607-14. PubMed ID: 26324692
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.